Login / Signup

Generalisability of trials on antithrombotic treatment intensification in patients with cardiovascular disease.

Maria C CastelijnsSteven H J HagemanMartin TeraaManon G van der MeerJan WesterinkJurrien M Ten BergFrank L J Visseren
Published in: Heart (British Cardiac Society) (2024)
A large proportion of contemporary CVD patients would be eligible for intensified antithrombotic treatment trials, with mostly similar adjusted event risks to ineligible patients. Trial-based guideline recommendations are largely applicable to real-world patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • peritoneal dialysis
  • clinical trial
  • type diabetes
  • coronary artery disease
  • climate change
  • clinical practice
  • open label
  • replacement therapy